Employees: 1,344
Size Fulgent Genetics (FLGT) is a United States Health Care company (Medical/Nursing Services) with a market value of $702M, the 2455th largest of 3,085 United States companies the cockpit tracks. Shares closed at $25.13 on 18 Nov 2026.
Performance Over six months the shares gained 53.1%, against -8.6% for the median peer and -2.2% for the United States market (cap-weighted) — 2nd highest of 21 in its peer set.
Growth Revenue grew 4.7% over the last twelve months (peer median +6.2%); the operating margin is -37.5% (peer median 8.2%).
Valuation It trades at 1.2× enterprise value to sales against a peer median of 1.6× (7th cheapest of 21).
Capital Return on invested capital runs 24.1 points below its cost of capital (10.0% WACC).
Short interest Short interest is 7.2% of the free float (30 Oct 2026).
Next results Next results expected around 26 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $330M | $323M | $283M | $289M | $619M |
| Revenue growth | — | +14% | -2% | -53% | — |
| Gross profit | $103M | $123M | $99.2M | $96.6M | $360M |
| EBITDA | -$97.4M | -$67.0M | -$49.0M | -$43.5M | $218M |
| Net income | -$90.9M | -$60.5M | -$42.7M | -$168M | $143M |
| Free cash flow | -$1.40M | -$124M | -$19.3M | $4.80M | $235M |
| Capital expenditure | $15.8M | $22.6M | $40.3M | $22.2M | $18.8M |
| Total debt | $10.4M | $8.04M | $9.23M | $14.9M | $41.1M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | FLGT | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +23.6% | -1.8% | highest of 21 |
| 6-month return | +53.1% | -8.6% | 2nd highest of 21 |
| Distance from 52-week high | -19.0% | -30.8% | 6th highest of 21 |
| Revenue growth (TTM) | +4.7% | +6.2% | 10th lowest of 21 |
| Operating margin | -37.5% | 8.2% | 3rd lowest of 21 |
| EV / Sales | 1.2× | 1.6× | 7th cheapest of 21 |
| ROIC minus cost of capital | -24.1 pp | -0.1 pp | 2nd lowest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Fulgent Genetics FLGT | United States | $702M | +53% | +5% | -38% | 1.2× | n/a | n/a |
| Nephrocare Health Services NEPHROPLUS.NS | India | $702M | +1% | +33% | 13% | 5.6× | 36.6% | +31.6% |
| GMR Solutions GMRS | United States | $714M | -8% | -4% | 14% | 0.9× | -19.6% | -4.0% |
| WELL Health Technologies WELL.TO | Canada | $661M | -9% | +29% | 6% | 1.2× | 10.1% | +94.5% |
| Jinxin Fertility 1951.HK | Hong Kong | $758M | -4% | +7% | 11% | 2.8× | 17.8% | +12.4% |
| HK inno.N 195940.KS | South Korea | $783M | -28% | +7% | 12% | 1.3× | -4.7% | +12.2% |
| Terveystalo Oy TTALO.HE | Finland | $832M | -26% | -8% | 8% | 1.2× | -5.1% | +5.3% |
| Thyrocare Technologies THYROCARE.NS | India | $858M | +7% | +22% | 26% | 8.5× | 28.5% | +10.9% |
| Ginkgo Bioworks DNA | United States | $547M | +9% | -44% | -242% | 6.5× | n/a | n/a |
| BML 4694.T | Japan | $932M | +12% | +4% | 7% | 0.7× | -9.0% | +1.6% |
| Shanghai Labway Clinical Laboratory 301060.SZ | China | $518M | -17% | -19% | 6% | 2.3× | 5.9% | +3.2% |
| Regis Healthcare REG.AX | Australia | $962M | -28% | +17% | 4% | 0.9× | 13.3% | +14.4% |
| AdaptHealth AHCO | United States | $1.01B | -30% | -3% | 3% | 0.9× | 16.8% | +25.2% |
| Novogene 688315.SS | China | $1.01B | +13% | +6% | 7% | 2.2× | 13.9% | +8.2% |
| JS Link 127120.KS | South Korea | $458M | -62% | +39% | -83% | 25.2× | n/a | n/a |
| Strata Critical Medical SRTA | United States | $443M | -10% | +23% | -4% | 1.4× | n/a | n/a |
| GoodRx GDRX | United States | $1.15B | +33% | -2% | 12% | 1.8× | 6.3% | +7.7% |
| Australian Clinical Labs ACL.AX | Australia | $418M | +68% | -1% | 8% | 1.3× | 4.3% | +2.6% |
| Nutex Health NUTX | United States | $1.19B | +42% | -19% | 39% | 1.8× | -18.0% | +253.5% |
| Integral Diagnostics IDX.AX | Australia | $413M | -22% | +26% | 9% | 1.5× | 7.8% | +17.7% |
| Jeena Sikho Lifecare JSLL.NS | India | $394M | -55% | +135% | 32% | 4.0× | 7.3% | +42.6% |